BioPharmSignal logoBioPharmSignal

Biotech News

Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference

Day One Biopharmaceuticals (DAWN)Day One BiopharmaceuticalsConference / presentation

BRISBANE, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that

Related news

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

MMSIMerit Medical2026-08-05 16:00 EST

Merit Medical to Participate in Upcoming Investors Conferences in August

ANGOAngioDynamics2026-07-28 12:30 EST

AngioDynamics to Participate in Upcoming Investor Conferences

GSKGSK plc2026-07-29 09:08 EST

Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

View all latest news

Day One Biopharmaceuticals

Pediatric and Rare Oncology Day One Biopharmaceuticals develops targeted therapies for cancers affecting children and adults. The company was founded around pediatric oncology and is expanding into additional rare tumor types. OJEMDA OJEMDA is a type II RAF inhibitor approved for relapsed or refractory pediatric low-grade glioma with an...

Recent company news

DAWNDay One Biopharmaceuticals2026-03-06 13:30 EST

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio

DAWNDay One Biopharmaceuticals2026-02-24 21:00 EST

Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance

DAWNDay One Biopharmaceuticals2026-02-10 13:30 EST

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

DAWNDay One Biopharmaceuticals2026-01-11 22:00 EST

Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance

DAWNDay One Biopharmaceuticals2026-01-06 14:02 EST

Day One Completes Acquisition of Mersana Therapeutics

Stock data

Close
21.53 USD
Market cap
2.22B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States